'Evergreening' and 'patent thicketing' aren't keeping cheaper generics out of patients' hands. - C4IP
C4IP pushes back against myths on patents' impact on drug prices, addressing claims of 'patent thickets' and 'evergreening' as misleading abuses by pharmaceutical companies.
Pharmaceutical companies protecting their market share with patent portfolios is a common practice, comparing it to Apple's iPhone being safeguarded by around 200 patents initially.
[
add
]
[
|
|
...
]